Bibliography
- Rampone B, Schiavone B, Martino A, Current management strategy of hepatocellular carcinoma. World J Gastroenterol 2009;15:3210-16
- Llovet JM, Di Bisceglie AM, Bruix J, Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008;100:698-711
- NCCN Practice Guidelines in Oncology v.1.2010. Available from: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp
- Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003;362:1907-17
- Yang JD, Roberts LR. Hepatocellular carcinoma: a global view. Nat Rev Gastroenterol Hepatol 2010;7:448-58
- Yao FY. Liver transplantation for hepatocellular carcinoma: beyond the Milan criteria. Am J Transplant 2008;8:1982-9
- Befeler AS, Hayashi PH, Di Bisceglie AM. Liver transplantation for hepatocellular carcinoma. Gastroenterology 2005;128:1752-64
- Silva M, Moya A, Berenguer M, Expanded criteria for liver transplantation in patients with cirrhosis and hepatocellular carcinoma. Liver Transpl 2008;14:1449-60
- Schwartz M, Roayaie S, Llovet J. How should patients with hepatocellular carcinoma recurrence after liver transplantation be treated?J Hepatol 2005;43:584-9
- Zimmerman MA, Ghobrial RM, Tong MJ, Recurrence of hepatocellular carcinoma following liver transplantation: a review of preoperative and postoperative prognostic indicators. Arch Surg 2008;143:182-8
- Stone MJ, Klintmalm GB, Polter D, Neoadjuvant chemotherapy and liver transplantation for hepatocellular carcinoma: a pilot study in 20 patients. Gastroenterology 1993;104:196-202
- Roayaie S, Frischer JS, Emre SH, Long-term results with multimodal adjuvant therapy and liver transplantation for the treatment of hepatocellular carcinomas larger than 5 centimeters. Ann Surg 2002;235:533-9
- Cherqui D. Role of adjuvant treatment in liver transplantation for advanced hepatocellular carcinoma. J Hepatobiliary Pancreat Surg 1998;5:35-40
- Soderdahl G, Backman L, Isoniemi H, A prospective, randomized, multi-centre trial of systemic adjuvant chemotherapy versus no additional treatment in liver transplantation for hepatocellular carcinoma. Transpl Int 2006;19:288-94
- Treiber G. mTOR inhibitors for hepatocellular cancer: a forward-moving target. Expert Rev Anticancer Ther 2009;9:247-61
- Vezina C, Kudelski A, Sehgal SN. Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. J Antibiot (Tokyo) 1975;28:721-6
- Alamo JM, Barrera L, Casado MD, Efficacy, tolerance, and safety of mammalian target of rapamycin inhibitors as rescue immunosuppressants in liver transplantation. Transplant Proc 2009;41:2181-3
- MacKenzie AR, von Mehren M. Mechanisms of mammalian target of rapamycin inhibition in sarcoma: present and future. Expert Rev Anticancer Ther 2007;7:1145-54
- Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2002;2:489-501
- Huang S, Houghton PJ. Targeting mTOR signaling for cancer therapy. Curr Opin Pharmacol 2003;3:371-7
- Thomas GV. mTOR and cancer: reason for dancing at the crossroads?Curr Opin Genet Dev 2006;16:78-84
- Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev 2004;18:1926-45
- Kwiatkowski DJ. Tuberous sclerosis: from tubers to mTOR. Ann Hum Genet 2003;67:87-96
- Kwiatkowski DJ. Rhebbing up mTOR: new insights on TSC1 and TSC2, and the pathogenesis of tuberous sclerosis. Cancer Biol Ther 2003;2:471-6
- Inoki K, Li Y, Xu T, Guan KL. Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes Dev 2003;17:1829-34
- Geissler EK, Schlitt HJ, Thomas G. mTOR, cancer and transplantation. Am J Transplant 2008;8:2212-18
- Brugarolas J, Kaelin WG Jr. Dysregulation of HIF and VEGF is a unifying feature of the familial hamartoma syndromes. Cancer Cell 2004;6:7-10
- Corradetti MN, Inoki K, Bardeesy N, Regulation of the TSC pathway by LKB1: evidence of a molecular link between tuberous sclerosis complex and Peutz-Jeghers syndrome. Genes Dev 2004;18:1533-8
- Schmelzle T, Hall MN. TOR, a central controller of cell growth. Cell 2000;103:253-62
- Geissler EK. The impact of mTOR inhibitors on the development of malignancy. Transplant Proc 2008;40:S32-5
- Gambacorti-Passerini CB, Gunby RH, Piazza R, Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias. Lancet Oncol 2003;4:75-85
- Lang SA, Gaumann A, Koehl GE, Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model. Int J Cancer 2007;120:1803-10
- Zhong H, Chiles K, Feldser D, Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res 2000;60:1541-5
- Hara K, Maruki Y, Long X, Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell 2002;110:177-89
- Kim DH, Sarbassov DD, Ali SM, mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 2002;110:163-75
- Sarbassov DD, Ali SM, Kim DH, Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol 2004;14:1296-302
- Sarbassov DD, Guertin DA, Ali SM, Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005;307:1098-101
- Bjornsti MA, Houghton PJ. The TOR pathway: a target for cancer therapy. Nat Rev Cancer 2004;4:335-48
- Thoreen CC, Kang SA, Chang JW, An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J Biol Chem 2009;284:8023-32
- Chresta CM, Davies BR, Hickson I, AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. Cancer Res 2010;70:288-98
- Feldman ME, Apsel B, Uotila A, Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol 2009;7:e38
- Garcia-Martinez JM, Alessi DR. mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1). Biochem J 2008;416:375-85
- Yu K, Toral-Barza L, Shi C, Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin. Cancer Res 2009;69:6232-40
- Liu P, Cheng H, Roberts TM, Zhao JJ. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 2009;8:627-44
- Sarbassov DD, Ali SM, Sengupta S, Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 2006;22:159-68
- Shor B, Zhang WG, Toral-Barza L, A new pharmacologic action of CCI-779 involves FKBP12-independent inhibition of mTOR kinase activity and profound repression of global protein synthesis. Cancer Res 2008;68:2934-43
- Faivre S, Kroemer G, Raymond E. Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov 2006;5:671-88
- Raymond E, Alexandre J, Faivre S, Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol 2004;22:2336-47
- Semela D, Piguet AC, Kolev M, Vascular remodeling and antitumoral effects of mTOR inhibition in a rat model of hepatocellular carcinoma. J Hepatol 2007;46(5):840-8
- Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell 2006;124:471-84
- Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell 2007;12:9-22
- Sarbassov DD, Ali SM, Sabatini DM. Growing roles for the mTOR pathway. Curr Opin Cell Biol 2005;17:596-603
- Brazelton TR, Morris RE. Molecular mechanisms of action of new xenobiotic immunosuppressive drugs: tacrolimus (FK506), sirolimus (rapamycin), mycophenolate mofetil and leflunomide. Curr Opin Immunol 1996;8:710-20
- Sehgal SN. Sirolimus: its discovery, biological properties, and mechanism of action. Transplant Proc 2003;35:7S-14S
- Sho M, Samsonov DV, Briscoe DM. Immunologic targets for currently available immunosuppressive agents: what is the optimal approach for children?Semin Nephrol 2001;21:508-20
- Gingras AC, Raught B, Sonenberg N. eIF4 initiation factors: effectors of mRNA recruitment to ribosomes and regulators of translation. Annu Rev Biochem 1999;68:913-63
- Mita MM, Mita AC, Chu QS, Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies. J Clin Oncol 2008;26:361-7
- Shah OJ, Hunter T. Tuberous sclerosis and insulin resistance. Unlikely bedfellows reveal a TORrid affair. Cell Cycle 2005;4:46-51
- Sahin F, Kannangai R, Adegbola O, mTOR and P70 S6 kinase expression in primary liver neoplasms. Clin Cancer Res 2004;10(24):8421-5
- Sieghart W, Fuereder T, Schmid K, Mammalian target of rapamycin pathway activity in hepatocellular carcinomas of patients undergoing liver transplantation. Transplantation 2007;83:425-32
- Baba HA, Wohlschlaeger J, Cicinnati VR, Phosphorylation of p70S6 kinase predicts overall survival in patients with clear margin-resected hepatocellular carcinoma. Liver Int 2009;29:399-405
- Villanueva A, Chiang DY, Newell P, Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology 2008;135:1972-83
- Zhang JF, Liu JJ, Lu MQ, Rapamycin inhibits cell growth by induction of apoptosis on hepatocellular carcinoma cells in vitro. Transpl Immunol 2007;17:162-8
- Newell P, Toffanin S, Villanueva A, Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo. J Hepatol 2009;51:725-33
- Available from: http://clinicaltrials.gov/ct2/results?term=everolimus&recr=&rslt=&type=&cond=HCC&intr=&outc=&lead=&spons=&id=&state1=&cntry1=&state2=&cntry2=&state3=&cntry3=&locn=&gndr=&rcv_s=&rcv_e=&lup_s=&lup_e= [Accessed on March 2011]
- Available from: http://clinicaltrials.gov/ct2/results?term=sirolimus+HCC [Accessed on March 2011]
- Available from: http://clinicaltrials.gov/ct2/show/NCT01035229?term=everolimus&cond=HCC&rank=5 [Accessed on March 2011]
- Available from: http://clinicaltrials.gov/ct2/results?term=temsirolimus&recr=&rslt=&type=&cond=HCC&intr=&outc=&lead=&spons=&id=&state1=&cntry1=&state2=&cntry2=&state3=&cntry3=&locn=&gndr=&rcv_s=&rcv_e=&lup_s=&lup_e= [Accessed on March 2011]
- Available from: http://clinicaltrials.gov/ct2/show/NCT00999882?term=AZD8055&cond=hcc&rank=1 [Accessed on March 2011]
- Available from: http://clinicaltrials.gov/ct2/show/NCT01009801?term=hcc+tace+everolimus&rank=2 [Accessed on March 2011]
- Hudes GR. Targeting mTOR in renal cell carcinoma. Cancer 2009;115:2313-20
- Dunn C, Croom KF. Everolimus: a review of its use in renal and cardiac transplantation. Drugs 2006;66:547-70
- Novartis Pharmaceuticals. Afinitor [everolimus] package insert. East Hanover; NJ: 2009
- Boni J, Leister C, Burns J, Pharmacokinetic profile of temsirolimus with concomitant administration of cytochrome p450-inducing medications. J Clin Pharmacol 2007;47:1430-9
- Gabardi S, Baroletti SA. Everolimus: a proliferation signal inhibitor with clinical applications in organ transplantation, oncology, and cardiology. Pharmacotherapy 2010;30:1044-56
- Zeiser R, Leveson-Gower DB, Zambricki EA, Differential impact of mammalian target of rapamycin inhibition on CD4+CD25+Foxp3+ regulatory T cells compared with conventional CD4+ T cells. Blood 2008;111:453-62
- Guba M, von Breitenbuch P, Steinbauer M, Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002;8:128-35
- Koehl GE, Andrassy J, Guba M, Rapamycin protects allografts from rejection while simultaneously attacking tumors in immunosuppressed mice. Transplantation 2004;77:1319-26
- Kneteman NM, Oberholzer J, Al Saghier M, Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma. Liver Transpl 2004;10:1301-11
- Wall WJ. Hepatocellular cancer, transplantation, and sirolimus. Liver Transpl 2004;10:1312-14
- Vivarelli M, Dazzi A, Cucchetti A, Sirolimus in liver transplant recipients: a large single-center experience. Transplant Proc 2010;42:2579-84
- Toso C, Merani S, Bigam DL, Sirolimus-based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma. Hepatology 2010;51:1237-43
- Available from: http://clinicaltrials.gov/ct2/show/NCT00355862?term=mtor&cond=liver+transplant+hcc&rank=1 [Accessed on March 2011]
- Available from: http://clinicaltrials.gov/ct2/show/NCT00328770?term=sirolimus&cond=liver+transplant&rank=8 [Accessed on March 2011]
- Available from: ((http://clinicaltrials.gov/ct2/show/NCT00554125?term=sirolimus&cond=liver+transplant&rank=10 [Accessed on March 2011]
- Schnitzbauer AA, Zuelke C, Graeb C, A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma. BMC Cancer 2010;11:190
- Starling RC, Hare JM, Hauptman P, Therapeutic drug monitoring for everolimus in heart transplant recipients based on exposure-effect modeling. Am J Transplant 2004;4:2126-31
- Lorber MI, Ponticelli C, Whelchel J, Therapeutic drug monitoring for everolimus in kidney transplantation using 12- month exposure, efficacy, and safety data. Clin Transplant 2005;19:145-52
- Levy G, Schmidli H, Punch J, Safety, tolerability, and efficacy of everolimus in de novo liver transplant recipients: 12- and 36-month results. Liver Transpl 2006;12:1640-8
- De Simone P, Carrai P, Precisi A, Conversion to everolimus monotherapy in maintenance liver transplantation: feasibility, safety, and impact on renal function. Transpl Int 2009;22:279-86
- Koehl GE, Gaumann A, Zuelke C, Development of de novo cancer in p53 knock-out mice is dependent on the type of long-term immunosuppression used. Transplantation 2006;82:741-8
- Morales JM, Campistol JM, Kreis H, Sirolimus-based therapy with or without cyclosporine: long-term follow-up in renal transplant patients. Transplant Proc 2005;37:693-6
- Mathew T, Kreis H, Friend P. Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies. Clin Transplant 2004;18(4):446-9
- Kahan BD, Yakupoglu YK, Schoenberg L, Low incidence of malignancy among sirolimus/cyclosporine-treated renal transplant recipients. Transplantation 2005;80:749-58
- Yakupoglu YK, Buell JF, Woodle S, Individualization of immunosuppressive therapy. III. Sirolimus associated with a reduced incidence of malignancy. Transplant Proc 2006;38:358-61
- Pirsch JD. Cytomegalovirus infection and posttransplant lymphoproliferative disease in renal transplant recipients: results of the U.S. multicenter FK506 Kidney Transplant Study Group. Transplantation 1999;68:1203-5
- Kauffman HM, Cherikh WS, Cheng Y, Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation 2005;80:883-9
- Sanchez-Fructuoso A, Conesa J, Perez Flores I, Conversion to sirolimus in renal transplant patients with tumors. Transplant Proc 2006;38:2451-2
- Gomez-Camarero J, Salcedo M, Rincon D, Use of everolimus as a rescue immunosuppressive therapy in liver transplant patients with neoplasms. Transplantation 2007;84:786-91
- Boratynska M, Watorek E, Smolska D, Anticancer effect of sirolimus in renal allograft recipients with de novo malignancies. Transplant Proc 2007;39:2736-9
- Bonatti H, Hoefer D, Rogatsch H, Successful management of recurrent Epstein-Barr virus-associated multilocular leiomyosarcoma after cardiac transplantation. Transplant Proc 2005;37:1839-44
- Toh HC, Teo M, Ong KW, Use of sirolimus for Epstein-Barr virus-positive smooth-muscle tumour. Lancet Oncol 2006;7:955-7
- Babel N, Eibl N, Ulrich C, Development of Kaposi's sarcoma under sirolimus-based immunosuppression and successful treatment with imiquimod. Transpl Infect Dis 2008;10:59-62
- Gomez-Camarero J, Salcedo M, Rincon D, Use of everolimus as a rescue immunosuppressive therapy in liver transplant patients with neoplasms. Transplantation 2007;84:786-91
- Llovet JM, Ricci S, Mazzaferro V, Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90
- Bhoori S, Toffanin S, Sposito C, Personalized molecular targeted therapy in advanced, recurrent hepatocellular carcinoma after liver transplantation: a proof of principle. J Hepatol 2010;52:771-5
- Hoshida Y, Toffanin S, Lachenmayer A, Molecular classification and novel targets in hepatocellular carcinoma: recent advancements. Semin Liver Dis 2010;30:35-51
- Wang Z, Zhou J, Fan J, Effect of rapamycin alone and in combination with sorafenib in an orthotopic model of human hepatocellular carcinoma. Clin Cancer Res 2008;14:5124-30
- Huynh H, Ngo VC, Koong HN, AZD6244 enhances the anti-tumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC). J Hepatol 2010;52:79-87
- Huynh H, Ngo VC, Koong HN, Sorafenib and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma. J Cell Mol Med 2009;13:2673-83
- Lathia C, Lettieri J, Cihon F, Lack of effect of ketoconazole-mediated CYP3A inhibition on sora- fenib clinical pharmacokinetics. Cancer Chemother Pharmacol 2006;57:685-92
- Van Erp NP, Baker SD, Zandvliet AS, Marginal increase of sunitinib exposure by grapefruit juice. Cancer Chemother Pharmacol 2011;67:695-703
- Gangadhar TC, Cohen EE, Wu K, Two drug interaction studies of sirolimus in combination with sorafenib or sunitinib in patients with advanced malignancies. Clin Cancer Res 2011;17:1956-63
- Saidi RF, Shah SA, Rawson AP, Treating hepatocellular carcinoma with sorafenib in liver transplant patients: an initial experience. Transplant Proc 2010;42:4582-4
- Borentain P, Gregoire E, Hardwigsen J, Liver transplantation in a patient treated by sorafenib for hepatocellular carcinoma. Clin Res Hepatol Gastroenterol 2011; 35(3):234-6
- Available from: http://www.edhayes.com/CYP450-2.html
- Sankhala K, Mita A, Kelly K, The emerging safety profile of mTOR inhibitors, a novel class of anticancer agents. Target Oncol 2009;4:135-42